Drugs / Infanrix-IPV/Hib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02858440 | Sep 2016 → Oct 2017 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Infanrix-IPV/Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02858440 ↗ |
| Modality | Vaccine | “Combined Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus and Haemophilus Influenzae Type b (DTPa-IPV/Hib) Conjugate Vaccine” NCT02858440 ↗ |
| Route | Intramuscular | “The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.” NCT02858440 ↗ |